- Home
- TRAW vs BMRA Comparison
TRAW vs BMRA Comparison
Compare TRAW & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRAW
- BMRA
- Stock Information
- Founded
- TRAW 1998
- BMRA 1971
- Country
- TRAW United States
- BMRA United States
- Employees
- TRAW N/A
- BMRA N/A
- Industry
- TRAW
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TRAW
- BMRA Health Care
- Exchange
- TRAW NYSE
- BMRA Nasdaq
- Market Cap
- TRAW 8.6M
- BMRA 8.1M
- IPO Year
- TRAW 2013
- BMRA N/A
- Fundamental
- Price
- TRAW $1.58
- BMRA $3.91
- Analyst Decision
- TRAW
- BMRA
- Analyst Count
- TRAW 0
- BMRA 0
- Target Price
- TRAW N/A
- BMRA N/A
- AVG Volume (30 Days)
- TRAW 71.7K
- BMRA 95.1K
- Earning Date
- TRAW 08-14-2025
- BMRA 08-27-2025
- Dividend Yield
- TRAW N/A
- BMRA N/A
- EPS Growth
- TRAW N/A
- BMRA N/A
- EPS
- TRAW N/A
- BMRA N/A
- Revenue
- TRAW $227,000.00
- BMRA $5,678,000.00
- Revenue This Year
- TRAW $3.81
- BMRA N/A
- Revenue Next Year
- TRAW $30.43
- BMRA N/A
- P/E Ratio
- TRAW N/A
- BMRA N/A
- Revenue Growth
- TRAW 0.44
- BMRA 5.01
- 52 Week Low
- TRAW $0.97
- BMRA $1.93
- 52 Week High
- TRAW $19.44
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- TRAW 50.55
- BMRA 63.63
- Support Level
- TRAW $1.47
- BMRA $3.50
- Resistance Level
- TRAW $1.73
- BMRA $4.24
- Average True Range (ATR)
- TRAW 0.10
- BMRA 0.25
- MACD
- TRAW 0.01
- BMRA 0.09
- Stochastic Oscillator
- TRAW 50.00
- BMRA 74.62
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.